PURPOSE: Recently, target therapy, representative of the (Epidermal Growth Factor Receptor )EGFR inhibitor, has provided new thearpy options for advanced lung cancer patients. Research reports that the gene mutation of the EGFR tyrosine kinase coding region is the premise for this target therapy. This procedure not only detects the gene mutation of tumor tissue and metastatic lymph nodes in lung cancer patients, but also researches the correlation between mutation of lymph nodes and tumor tissue.
METHODS: Collect 24 samples of normal lung tissue and 24 samples of tumor and metastatic lymph nodes tissue from lung cancer patients within transferred lymph nodes. Use PCR amplication and gene suquencing methods to analyse gene mutation for extrons 19 and 21 of the EGFR.
RESULTS: Gene mutation of EGFR extron in normal lung tissue was wild-type, and detection rate for EGFR extron gene mutation in lung cancer tissue was 20.8%(5/24). Extron 19 mutation was 4%(1/24),and extron 21 mutation was 16.6%(4/24). Mutation of extron 19 was basyl deletion mutation, on the 746–753 codons. Extron 21 mutation was basyl replacement mutation, which was found on the 858 codon. Research suggests gene mutation for EGFR is typically in adenocarcinoma and adenosquamous carcinoma of lung(45.5%). There was no correlation existed between gene mutation of extron and the patient's sex and age one. sample mutated in all 21 samples of lymph nodes tissue, and it had affinis mutation with in its primary tumor tissue. But the other four samples of tumor tissues with detected gene mutation, never detected gene mutation in their metastatic lymph node samples.
CONCLUSION: Gene mutation rate for EGFR is about 20% in lung cancer. Mutation is common in adenocarcinoma and adenosquamous carcinoma of the lung.
CLINICAL IMPLICATIONS: Detection of gene mutation for EGFR in metastatic lymph node tissues can not indicate the mutation type of its primary lung cancer tissues .
DISCLOSURE: Zhe Chen, None.